IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary

IN8bio (Nasdaq: INAB) has announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10, 2024. The presentation will focus on INB-100, a pilot study of donor-derived gamma-delta T cell therapy following haploidentical hematopoietic stem-cell transplantation. Dr. Joseph McGuirk from The University of Kansas Cancer Center will present Abstract #4823 in the Cellular Immunotherapies session on December 9, 2024, from 6:00 PM to 8:00 PM PDT. The abstract will be available online through ASH's website, with poster reprints accessible on IN8bio's website after the presentation.

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66^th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA.

Details for the ASH 2024 presentation are as follows:

	Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide
	Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center
	Abstract #: 4823
	Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
	Date and Time: Monday, December 9, 2024, 6:00 PM - 8:00 PM PDT

The abstract will be available online and can be accessed via the conference websites at ASH Annual Meeting Abstracts. Reprints of the poster will also be accessible on the Events & Presentations page of IN8bio’s website following the presentations.

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogenic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit www.IN8bio.com.

Investors & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com

Patrick McCall
IN8bio, Inc.
646.933.5603
pfmccall@IN8bio.com

Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

When is IN8bio (INAB) presenting at the 2024 ASH Annual Meeting?

IN8bio will present on Monday, December 9, 2024, from 6:00 PM to 8:00 PM PDT at the ASH Annual Meeting in San Diego.

What is the subject of IN8bio's (INAB) presentation at ASH 2024?

The presentation focuses on INB-100, a pilot study of donor-derived gamma-delta T cell therapy following haploidentical hematopoietic stem-cell transplantation.

Who is presenting IN8bio's (INAB) research at ASH 2024?

Dr. Joseph McGuirk from The University of Kansas Cancer Center will present Abstract #4823 at the ASH Annual Meeting.

Where can investors find IN8bio's (INAB) ASH 2024 presentation materials?

The abstract will be available on the ASH Annual Meeting website, and poster reprints will be accessible on IN8bio's website Events & Presentations page after the presentation.